RU2527970C2 - Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена - Google Patents

Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена Download PDF

Info

Publication number
RU2527970C2
RU2527970C2 RU2011126173/04A RU2011126173A RU2527970C2 RU 2527970 C2 RU2527970 C2 RU 2527970C2 RU 2011126173/04 A RU2011126173/04 A RU 2011126173/04A RU 2011126173 A RU2011126173 A RU 2011126173A RU 2527970 C2 RU2527970 C2 RU 2527970C2
Authority
RU
Russia
Prior art keywords
salt
hcl
citrate
batch
ray diffraction
Prior art date
Application number
RU2011126173/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2011126173A (ru
Inventor
Брайан ДИМОК
Чэн Хсиа Анджелина ЛИ
Энтони Деодауния ВИЛЬЯМ
Original Assignee
Селл Терапьютикс,Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селл Терапьютикс,Инк. filed Critical Селл Терапьютикс,Инк.
Publication of RU2011126173A publication Critical patent/RU2011126173A/ru
Application granted granted Critical
Publication of RU2527970C2 publication Critical patent/RU2527970C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
RU2011126173/04A 2008-12-11 2009-12-09 Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена RU2527970C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
US61/121,668 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (2)

Publication Number Publication Date
RU2011126173A RU2011126173A (ru) 2013-01-20
RU2527970C2 true RU2527970C2 (ru) 2014-09-10

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011126173/04A RU2527970C2 (ru) 2008-12-11 2009-12-09 Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена

Country Status (23)

Country Link
US (2) US8980873B2 (OSRAM)
EP (1) EP2376499B1 (OSRAM)
JP (1) JP5669748B2 (OSRAM)
KR (1) KR101729918B1 (OSRAM)
CN (1) CN102282148B (OSRAM)
AR (2) AR074724A1 (OSRAM)
AU (1) AU2009325147B2 (OSRAM)
BR (1) BRPI0922736B1 (OSRAM)
CA (1) CA2746058C (OSRAM)
DK (1) DK2376499T3 (OSRAM)
ES (1) ES2536558T3 (OSRAM)
HR (1) HRP20150428T1 (OSRAM)
IL (3) IL213418A0 (OSRAM)
MX (1) MX2011006206A (OSRAM)
MY (1) MY160005A (OSRAM)
NZ (1) NZ593223A (OSRAM)
PL (1) PL2376499T3 (OSRAM)
PT (1) PT2376499E (OSRAM)
RU (1) RU2527970C2 (OSRAM)
SG (1) SG171907A1 (OSRAM)
TW (1) TWI449705B (OSRAM)
WO (1) WO2010068181A1 (OSRAM)
ZA (1) ZA201104032B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376499B1 (en) 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
WO2010068182A1 (en) * 2008-12-11 2010-06-17 S*Bio Pte Ltd 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
EP2837632B1 (en) 2012-04-13 2016-05-18 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004116311A (ru) * 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
EA005529B1 (ru) * 2001-05-14 2005-04-28 Пфайзер Продактс Инк. Цитрат 5,8,14-триазатетрацикло-(10.3.1.0.0)-гексадека-2(11),3,5,7,9-пентаена
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
EP2376499B1 (en) 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005529B1 (ru) * 2001-05-14 2005-04-28 Пфайзер Продактс Инк. Цитрат 5,8,14-триазатетрацикло-(10.3.1.0.0)-гексадека-2(11),3,5,7,9-пентаена
RU2004116311A (ru) * 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
WO2010068181A1 (en) 2010-06-17
CA2746058C (en) 2016-05-17
BRPI0922736B1 (pt) 2022-02-22
PT2376499E (pt) 2015-06-03
KR101729918B1 (ko) 2017-04-25
US20110294831A1 (en) 2011-12-01
RU2011126173A (ru) 2013-01-20
BRPI0922736A2 (pt) 2017-10-31
ZA201104032B (en) 2012-08-29
JP5669748B2 (ja) 2015-02-12
EP2376499A1 (en) 2011-10-19
KR20110106344A (ko) 2011-09-28
AR074724A1 (es) 2011-02-09
MY160005A (en) 2017-02-15
SG171907A1 (en) 2011-07-28
AU2009325147B2 (en) 2014-08-14
CN102282148B (zh) 2014-12-24
ES2536558T3 (es) 2015-05-26
TWI449705B (zh) 2014-08-21
PL2376499T3 (pl) 2015-07-31
DK2376499T3 (en) 2015-05-04
US8980873B2 (en) 2015-03-17
WO2010068181A8 (en) 2011-08-18
IL213418A0 (en) 2011-07-31
HK1161877A1 (en) 2012-08-10
HRP20150428T1 (xx) 2015-06-19
AR114133A2 (es) 2020-07-22
CA2746058A1 (en) 2010-06-17
US20150322084A1 (en) 2015-11-12
CN102282148A (zh) 2011-12-14
TW201028426A (en) 2010-08-01
EP2376499B1 (en) 2015-02-25
US9624242B2 (en) 2017-04-18
NZ593223A (en) 2013-08-30
JP2012511571A (ja) 2012-05-24
IL289379A (en) 2022-02-01
AU2009325147A1 (en) 2011-06-23
IL250310A0 (en) 2017-03-30
MX2011006206A (es) 2011-07-20
BRPI0922736A8 (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
JP2020100624A (ja) Ｌ−オルニチンフェニルアセテートおよびその製造方法
AU2014286047B2 (en) Crystalline forms of ponatinib hydrochloride
RU2527970C2 (ru) Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена
US8987243B2 (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt
KR20200140821A (ko) 아베마시클립의 고체-상태 형태, 그의 용도 및 제조
RU2543721C2 (ru) Цитратная соль 9е-15-(2-пирролидин-1-ил-этокси)-7,12,25-триокса-19,21,24-триазатетрацикло[18.3.1.1(2,5).1(14,18)]гексакоза-1(24),2,4,9,14,16,18(26),20,22-нонаена
US20240140966A1 (en) Amorphous and crystalline forms of mcl-1 antagonists
US20250073244A1 (en) Crystalline forms of pentaaza macrocyclic ring complex
CZ305096B6 (cs) Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
US20230265043A1 (en) Crystalline form of phentermine hydrochloride and process for obtaining same
WO2016113242A1 (en) Di-pidotimod benzathine and solid forms thereof
HK1161877B (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner